| |
|
| Source: Company documents |
|
|
| Name
: |
Daniel J. Levangie |
| Title
: |
Chairman of the Board |
| Since: |
02/2007 |
|
|
|
|
| Name
: |
Robert J. Palmisano |
| Title
: |
President and Chief Executive Officer, Director |
| Since: |
04/06/2008 |
|
|
|
|
| Name
: |
P. Richard Lunsford |
| Title
: |
Senior Vice President and President, US Commercial Operations |
| Since: |
10/2007 |
|
|
|
|
| Name
: |
Julie D. Tracy |
| Title
: |
Senior Vice President, Chief Communications Officer |
| Since: |
01/2008 |
|
|
|
|
| Name
: |
James M. Corbett |
| Title
: |
President, Chief Executive Officer, Director |
| Since: |
01/2005 |
|
|
|
|
| Name
: |
Patrick D. Spangler |
| Title
: |
Senior Vice President, Chief Financial Officer |
| Since: |
08/2007 |
|
|
|
|
| Name
: |
Stacy Enxing Seng |
| Title
: |
Senior Vice President and President, Peripheral Vascular and FoxHollow Technologies Divisions |
| Since: |
08/2007 |
|
|
|
|
| Name
: |
Pascal Girin |
| Title
: |
Senior Vice President and President - International |
| Since: |
08/2007 |
|
|
|
|
| Name
: |
Matthew Jenusaitis |
| Title
: |
Senior Vice President and President - Neurovascular Division |
| Since: |
08/2007 |
|
|
|
|
| Name
: |
Kevin M. Klemz |
| Title
: |
Senior Vice President, Chief Legal Officer, Secretary |
| Since: |
08/2007 |
|
|
|
|
| Name
: |
David H. Mowry |
| Title
: |
Senior Vice President, Corporate Manufacturing |
| Since: |
10/2007 |
|
|
|
|
| Name
: |
Gregory Morrison |
| Title
: |
Senior Vice President - Human Resources |
| Since: |
08/2007 |
|
|
|
|
|
|
|
| |
|
| Earnings
Release Dates : 5th August 2008 , 2nd May 2008 , 22nd February 2008 , 31st October 2007 |
|
 Audio |
|
|
| |
|
| |
|
| |
|
| |
| Caribou Coffee Goes Public This Week Sep 29, 1:39 PM ET |
| Micrus gains, Ev3 prices below range Jun 19, 3:18 AM ET |
| LHC Group's IPO Priced Atop Range, Gained Speed Jun 11, 11:41 AM ET |
|
| |
ev3, Inc.
The Company provides a broad portfolio of products that includes the important devices used in frequently performed procedures and also innovative devices for use in emerging therapies. The breadth of the Company’s portfolio enables it to address peripheral vascular device markets the Company currently estimate at approximately $1.0 billion worldwide. The Company believes that its broad portfolio of self-expanding and balloon expandable stents is differentiated from the other offerings due primarily to the radiopacity (visibility under fluoroscopy), placement accuracy, deliverability and their strong clinical performance.
|
| More... |
|
|
|
|
|
